Cardiac Management of the Patient With Duchenne Muscular Dystrophy

Author:

Buddhe Sujatha1,Cripe Linda23,Friedland-Little Joshua1,Kertesz Naomi23,Eghtesady Pirooz4,Finder Jonathan5,Hor Kan23,Judge Daniel P.6,Kinnett Kathi7,McNally Elizabeth M.8,Raman Subha3,Thompson W. Reid9,Wagner Kathryn R.10,Olson Aaron K.1

Affiliation:

1. Seattle Children’s Hospital and School of Medicine, University of Washington, Seattle, Washington;

2. Nationwide Children’s Hospital, Columbus, Ohio;

3. The Ohio State University, Columbus, Ohio;

4. St Louis Children’s Hospital and School of Medicine, Washington University, St Louis, Missouri;

5. Children’s Hospital of Pittsburgh and School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;

6. Medical University of South Carolina, Charleston, South Carolina;

7. Parent Project Muscular Dystrophy, Hackensack, New Jersey;

8. Feinberg School of Medicine, Northwestern University, Chicago, Illinois;

9. Johns Hopkins Hospital, Baltimore, Maryland; and

10. Kennedy Krieger Institute, School of Medicine, Johns Hopkins University, Baltimore, Maryland

Abstract

Duchenne muscular dystrophy (DMD) results in a progressive cardiomyopathy that produces significant morbidity and mortality. To improve the quality of life in patients with DMD, cardiac care is focused on surveillance and management, with the goal of slowing the onset and progression of heart failure complications. The current article is intended to be an expanded review on the cardiac management data used to inform the 2018 DMD Care Considerations recommendations as well as be a discussion on clinical controversies and future management directions. The new cardiac guidance includes changes regarding noninvasive imaging surveillance of cardiac function and pharmacologic therapy. Many emerging therapies lack sufficient evidence-based data to be recommended in the 2018 DMD Care Considerations. These are discussed in the present article as clinical controversies and future directions. Important emerging therapies include new heart failure medications, mechanical circulatory support with ventricular assist devices, heart transplantation, and internal cardiac defibrillators. Future research studies should be focused on the risks and benefits of these advanced therapies in patients with DMD. We conclude this review with a brief discussion on the relationship between the heart and the recently developed medications that are used to directly target the absence of dystrophin in DMD.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology, and Child Health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3